情報ルーム
情報ルームの記事を表示しています。

甲状腺疾患の放射性ヨード(ヨウ素)治療に関する指針(米国甲状腺学会)

このエントリーをはてなブックマークに追加

2011年04月08日(Fri) 05:08

甲状腺疾患の放射性ヨード(ヨウ素)治療に関する指針(米国甲状腺学会)が
雑誌「Thyroid」の最新号(2011年)に掲載されました。

http://www.liebertpub.com/products/product.aspx?pid=55


Public and Patient Safety Are Focus of New Radiation Treatment Practice Recommendations for Thyroid Disease Read accompanying commentary by Richard T. Kloos:
Survey of Radioiodine Therapy Safety Practices Highlights the Need for User-Friendly RecommendationNew Rochelle, NY, April 7, 2011—New recommendations from the American
Thyroid Association (ATA) on outpatient radioiodine (131I) treatment
aim to minimize unintended radiation exposure and maximize the safety
of patients, their families, and the public. The new ATA recommendations
are presented in the April issue of Thyroid, a peer-reviewed journal
published by Mary Ann Liebert, Inc. The ATA recommendations are available
free online.

The ATA convened a task force to update radiation safety information
related to outpatient 131 I therapy to treat hyperthyroidism and thyroid
cancer. The new ATA practice recommendations cover a broad range of topics
including travel; safety precautions at home, work, and school; personal
hygiene; and pregnancy and breastfeeding. These recommendations comply
with the most up-to-date U.S. Nuclear Regulatory Commission (NRC) regulations,
including a recent guidance statement that advises medical professionals
administering 131I therapy to ask patients about their intended destination
after the treatment and to discourage them from staying at hotels to limit
public radiation exposure.

In a Commentary in the February issue of Thyroid, Richard T. Kloos, MD, Professor,
The Ohio State University and Secretary/Chief Operating Officer of the ATA,
states that the new ATA document “aims to provide simplified, consistent,
and safe instructions for care providers and patients.”

"The strength of these practice recommendations is that the task force
included representatives across the range of disciplines that use radiation
to treat thyroid patients. It is essential that our patients receive clear
and consistent information from those ordering, administering, and monitoring
these treatments," states Gregory A. Brent, MD, Professor of Medicine and
Physiology, David Geffen School of Medicine at the University of California
Los Angeles and President of the ATA.


「論文」一覧に戻る